Genetic testing of PAX8 mutations associated with thyroid dysgenesis in Chinese congenital hypothyroidism patients by Li, Miaomiao et al.
  
ONLINE FIRST
This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.
ISSN: 0423-104X
e-ISSN: 2299-8306
Genetic Testing of PAX8 Mutations Associated with Thyroid
Dysgenesis in Chinese Congenital Hypothyroidism Patients
Authors:  Miaomiao Li, Fang Wang, Xiuli Wang, Yucui Zang, Wenmiao Wang,
Fengqi Wang, Lu Zhang, Qian Tang, Shiguo Liu, Dehua Zhao
DOI: 10.5603/EP.a2020.0004
Article type: Original Paper
Submitted: 2019-10-20
Accepted: 2020-01-06
Published online: 2020-02-25
This article has been peer reviewed and published immediately upon acceptance.
It is an open access article, which means that it can be downloaded, printed, and distributed freely,
provided the work is properly cited.
Articles in "Endokrynologia Polska" are listed in PubMed.
The final version may contain major or minor changes. 
Powered by TCPDF (www.tcpdf.org)
Genetic testing of PAX8 mutations associated with thyroid dysgenesis in Chinese 
congenital hypothyroidism patients 
 
Short title: Screening of PAX8 mutations in TD patients 
 
Miaomiao Li1, Fang Wang1, Xiuli Wang2, Yucui Zang1, Wenmiao Wang1, Fengqi 
Wang1, Lu Zhang1, Qian Tang1, Shiguo Liu1, Dehua Zhao3 
 
1The Affiliated Hospital of Qingdao University, Qingdao, China 
2The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China 
3Department of Obstetrics and Gynaecology, The Third Affiliated Hospital of 
Zhengzhou University, Zhengzhou, Henan, China 
 
Correspondence to: Shiguo Liu, The Affiliated Hospital of Qingdao University, No. 16 
Jiangsu Road, 266000 Qingdao, China; e-mail: liushiguo2002@126.com 
 
Abstract 
Background: Thyroid dysgenesis (TD) is the main cause of congenital hypothyroidism 
(CH), affecting nearly 1 in 2000–3000 newborns worldwide, as the most common 
neonatal endocrine disorder. Paired box gene 8 (PAX8), expressed during all stages of 
thyroid follicular cell, plays a key role in thyroid morphogenesis by a complex 
regulatory network. In conclusion, the genetic mechanism of PAX8 mutant in TD is still 
ambiguous; therefore, further research is needed.  
Material and methods: Blood samples were collected from 289 TD patients in 
Shandong Province, China. Genomic DNA was extracted from peripheral blood. All the 
exons of PAX8 along with their exon-intro boundaries were amplified by PCR and 
analysed by Sanger sequencing. 
Results: We identified three novel PAX8 nonsense mutations in three patients by 
sequence analysis of PAX8: Patient 1 (c.285C>G, p.Tyr95Ter), Patient 2 (c.747T>G, 
p.Tyr249Ter), and Patient 3 (c.786C>A, p.Tyr262Ter). All the three patients carrying 
PAX8 variants had obvious clinical phenotypes of thyroid anomaly, such as hypoplasia 
and athyreosis. 
Conclusion: We conducted the largest worldwide PAX8 mutation screening so far in 
TD patients. Three presumably pathogenic PAX8 mutations were detected in 289 TD 
cases for the first time, showing the mutation rate of PAX8 is 1.04% in Chinese TD 
patients. In addition, our study expands the gene mutation spectrum of TD. 
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Introduction 
Congenital hypothyroidism (CH) is the most common neonatal endocrine disorder 
affecting nearly 1 in 2000–3000 newborns worldwide, and the severe deficiency of 
thyroid hormone can lead to mental retardation and growth failure if not treated in a 
timely manner [1]. Thyroid dysgenesis (TD), the main cause of CH, accounting for 80–
85% of CH cases, caused by the abnormalities of thyroid gland development and 
migration, can be divided into three subtypes (agenesis, ectopy, and hypoplasia) 
according to the morphology and location of the thyroid gland [2].  
In humans, thyroid development can be divided into six stages: the thyroid anlage 
assembled by thyroid progenitors (E20–22); the appearance of the thyroid bud (E24); 
the migration of the thyroid (E30–40); the completion of thyroid migration (E45–50); 
thyroid bilobation and folliculogenesis (E60); and the completion of differentiation and 
organogenesis (E70) [3]. In this process, thyroid morphogenesis is a coordinated spatial 
and temporal process, which, when altered, can result in agenesis, ectopy, and 
hypoplasia [4, 5]. Various transcription factors play important roles in the thyroid 
development, especially haematopoietically expressed homeobox gene (HHEX), thyroid 
transcription factor 1 (TTF1/NKX2.1), thyroid transcription factor 2 (TTF2/FOXE1), 
and paired box gene 8 (PAX8), the expression of which can be detected at E20 and 
forms a complex regulatory network to induce morphological changes [6]. PAX8 
regulates the expression of FOXE1, HHEX, DUOX2, TG, and TPO [7–9] but can be 
regulated by HHEX and NKX2.1 simultaneously. In addition, PAX8 expression is 
autoregulated;  the cross-regulatory network ensures that PAX8 is a master regulator in 
thyroid development. Furthermore, mutations in PAX8 combined with NKX2.1, FOXE1, 
NKX2.5, TSHR, NTN1, JAG1, BOREALIN, and GLIS3 have been identified in patients 
with TD [10].     
PAX8 (NM_003466.4), located on human chromosome 2q12-q14, can be divided into 
12 exons. The PAX8 protein has a bipartite functionality consisting of a highly 
conserved DNA binding region in N-terminal and a transactivation region in C-terminal 
[11, 12]. Expressed during all stages of thyroid follicular cell (TFC) and in adults [13], 
PAX8 plays a key role in thyroid morphogenesis. In pax8-/- mice at E11.5, thyroid 
primordium appears to be much smaller (hypoplastic thyroid) than in wild-type and is 
essentially undetectable at E12.5 follicular cells [14, 15]. In vitro, PAX8 is a master 
gene for the regulation of the thyroid differentiated phenotype in several thyroid-derived 
cell lines [16]. Therefore, PAX8 is required for thyroid bud survival and TFC 
differentiation, and mutations in PAX8 may lead to TD [16, 17]. In the present study, we 
aimed to identify potential pathogenic PAX8 mutations in 289 Chinese children with 
TD, thereby providing insights into its aetiology.  
Materials and methods 
Patients 
Sixty-three TD patients were collected for screening variations in exon3 and exon4 of 
PAX8 in our preliminary study. In this research, we collected another 289 patients with 
TD identified through screening of newborns in Shandong Province from January 2015 
to November 2017. Neonatal screening for CH was proceeded in all of the subjects 72 
hours after birth with blood samples from the heel. Then the concentrations of thyroid-
stimulating hormone (TSH), free/total triiodothyronine (T3), and free/total thyroxine 
(T4) in serum were detected, respectively, using electro-chemiluminescence kits: 
Elecsys TSH, Elecsys FT3III, and Elecsys FT4III (Roche, German). The diagnosis of 
CH was based on a high serum TSH level (TSH ≥ 10 mIU/L) and a low fT4 level (fT4 < 
12 pmol/L). When the CH patients were three years old, they underwent thyroid 
echography and scintigraphy to establish the cause of CH. All the 289 patients selected 
for further research had been diagnosed as TD. The present study was approved by the 
Ethics Committee of the Affiliated Hospital of Qingdao University (2013-qdfy22). 
Informed consent was obtained from all individuals included in this study. The research 
related to human use complied with all the relevant national regulations and institutional 
policies, was in accordance the tenets of the Helsinki Declaration, and was approved by 
the authors' Institutional Review Board or equivalent committee. 
Methods 
Genomic DNA was extracted from peripheral blood with TIANGEN blood kit 
(TIANGEN, Beijing, China). All the exons of PAX8 along with their exon-intro 
boundaries were amplified by PCR, with the specific primer as Table 1. The PCR 
reaction solution contained 1  TransStart® FastPfu buffer with 0.2 mM dNTP, 1.25 
units of TransStart® FastPfu DNA polymerase, 50 ng Genomic DNA, and 0.2 μM of 
each primer; the total volume was 25 μl. The procedure of the PCR amplification was as 
follows: step 1 — denaturation at 95℃ for 2 min; step 2 — denaturation at 95℃ for 20 s; 
step 3 — annealing at primer-specific temperatures for 20 s; step 4 — extension at 72℃ 
for 20 s or 60 s; step 5 — incubated at 72℃ for 5 min. Steps 2 to 4 were cycled 35 
times. A BigDye® Terminator Cycle Sequencing Kit and automated sequencer ABI 
3730XL were used for the sequencing reaction of the PCR products. The sequencing 
results were interpreted using BioEdit software. 
Results and clinical report 
Genetic screening of PAX8 mutation 
A total of 289 TD patients were enrolled in this study, the ratio of male to female was 
1:1.05. According to the location and size of the thyroid gland, TD was classified into 
agenesis (120 cases, 41.5%), ectopy (94 cases, 32.5%), and hypoplasia (75 cases, 26%). 
Sanger sequencing analysis of PAX8 leading to the discovery of three novel PAX8 
variants in three patients: Patient 1 (NG_012384.1 (NM_003466.4): c.285C>G, 
p.Tyr95Ter); Patient 2 ( NG_012384.1 (NM_003466.4): c.747T>G, p.Tyr249Ter), and 
Patient 3 (NG_012384.1 (NM_003466.4): c.786C>A, p.Tyr262Ter); the sequence maps 
of the variants is shown in Figure 1. All the variants located in the evolutionary 
conserved protein domains of PAX8 were not detected in 200 control individuals or in 
the Exome Sequencing Project (ESP) or the 1000 Genomes Project databases.  
Analysis of the relationship between genotype and phenotype 
The three patients carrying PAX8 mutations had obvious clinical phenotype of thyroid 
anomaly, such as hypoplasia and athyreosis (Tab. 2). The medical records in detail are 
as follows. 
Patient 1, a female infant with p.Tyr95Ter mutation in PAX8, was born at 39 weeks 
of gestation by vaginal delivery with 3250 g birth weight. High TSH levels (208 
μIU/mL) were detected at five days of age during neonatal screening; she was recalled 
at 18 days of age for further evaluation, and the TSH serum level had increased to 384 
μIU/mL, the FT3 level was 2.28 pmol/L, and the FT4 level was 4.12 pmol/L. There was 
no family history of thyroid disease. Tc-99 m scans confirmed hypoplasia. 
Levothyroxine (L–T4) replacement therapy was started at an initial dose of 25 μg per 
day. We lost contact with this patient until 3.5 years of age. Then we contacted her 
parents and learned that the patient was receiving L–T4 33.3 μg replacement therapy. 
Half a year after withdrawal of L–T4 therapy, her TSH levels were outside the normal 
range for her age (five years). Therefore, L–T4 25 μg replacement therapy has been 
needed until now. 
Patient 2 with p.Tyr249Ter mutation was a female who weighed 3000 g at birth by 
vaginal delivery. She was recalled for further analysis after high TSH levels (232 
μIU/mL) were detected at six days of age during neonatal screening. At 13 days of age, 
TSH levels were 284 uIU/L, FT3 levels were 4.31 pmol/l, and FT4 levels were 8.71 
pmol/L. Therefore, L–T4 25 μg replacement therapy was started immediately with re-
examination of TSH levels per mouth. At two years old, she was diagnosed with 
permanent CH, and persistent treatment was prescribed because TSH levels were 
outside the normal range after a four-week withdrawal of L–T4 therapy. Tc-99 m scans 
showed hypoplasia. L–T4 30 ug replacement therapy was restarted. She is now 12 years 
old, and her physical and intellectual development are normal. The dosage of L–T4 was 
increased to 62.5 μg per day. 
Patient 3 was a male subject with a p.Tyr262Ter mutation. He was born at full-term 
by caesarean delivery, and his birth weight was 3750 g. Routine neonatal screening 
showed a high TSH level of 186 μIU/mL at three days of age. Then, the patient was 
recalled at 19 days to review the serum TSH level which had increased to 294 μIU/mL 
but the FT4 (2.8 pmol/L) and FT3 (2.2 pmol/L) levels were both low. L–T4 replacement 
therapy was started immediately at a dose of 25 μg. Tc-99 m scans detected an 
athyreosis. At two years of age, he was diagnosed with permanent CH. Now he is four 
years old, with normal physical and mental development. 
 
Discussion 
PAX8 induces thyroid morphogenesis by cooperating with other transcription factors, 
such as HHEX, NKX2.1, and FOXE1. The regulatory function of PAX8 is closely 
related to its molecular structure, which consists of two functional domains: a paired 
box domain for DNA binding; and an octapeptide and a residual paired type 
homeodomain for transaction. The paired box domain consists of 128 amino acids 
positioned between 9 and 137, the octapeptide is between 180 and 187, and the residual 
paired type homeodomain is between 228 and 250, all the domains are highly conserved 
in human PAX protein family [12, 18].  
The first description about PAX8 variants was conducted by Macchia in 1998; three 
mutations in two sporadic patients (p.R31H, p.L62R) and one familial case (p.R108X) 
resulted in severe reduction of the DNA-binding activity of PAX8, causing thyroid 
hypoplasia [19]. Vilain identified p.C57Y in a TD patient; the mutation resulted in loss 
of the ability to activate thyroid peroxidase (TPO) gene [20]. In these cases, PAX8 
mutations were inherited in an autosomal dominant manner. However, the same 
mutation site in a familial case may result in different clinical phenotypes. Esperante 
described a thyroid hypoplasia patient and his family carrying mutation p.T225M, while 
the father, brother, and sister were asymptomatic; and a thyroid agenesis patient and her 
mother carrying mutation p.G336S, while the mother was unaffected, suggesting that 
the variable penetrance or expressivity of the mutational carrier can be modulated not 
only by genetic but also by epigenetic factors [18]. In conclusion, the genetic 
mechanism of PAX8 mutant in TD is still ambiguous; therefore, more research is 
needed in future studies.   
In present study, all the patients carrying the novel variant of PAX8 had symptoms of 
obvious abnormal thyroid. Variant Y95X located at paired box domain, variant Y249X 
at homodomain, and variant Y262X at transactivation domain of PAX8 protein (Figure 
2) led to PAX8 dysfunction, with most or all of transactivation domain lost. Carrying 
the heterozygous variant, P1-3 was detected with high level of TSH during neonatal 
screening, and then P1 and P2 were diagnosed as hypoplasia by ultrasound examination; 
P3 was athyreosis. It is possible that the nonsense variants led to nonsense mediated 
decay of the mutated mRNA, thus the TD phenotype could be due to haploinsufficiency 
of PAX8 protein. The actual functional consequences of PAX8 truncating mutations are 
yet to be further investigated, and thus more experiments in vitro are still needed for 
pathologic study.  
Because PAX8 plays a key role in thyroid morphogenesis, many researches have 
screened PAX8 mutations in a large number of CH patients to get the mutational 
frequencies and relationship between genotypes and phenotypes. Kumorowicz-Czoch 
found two novel heterozygous substitutions (c.68G>A, p.G23D; c.*416C > T) in 48 
Polish CH patients, and the PAX8 mutation rate is 4.17% [21], while Al Taji E 
identified a novel mutation (c.155G>C, p.R52P) in 170 CH patients, and the PAX8 
mutation rate in the Czech Republic is 0.6% [22]. In addition, Ramos HE analysed 35 
patients with thyroid hypoplasia in southern Brazil and identified a patient with PAX8 
mutation (c.155G>C; p.R52P), and suggested the mutation rate to be 2.9% [23].  Cangul 
and Kirsten Lanzerath did not find any PAX8 mutation in 120 CH patients in Pakistan 
and the United Kingdom and 95 CH patients in south-west Germany, respectively [24, 
25], showing the low mutation rate of PAX8 in these countries. All these findings 
confirmed the contribution of PAX8 mutations to the aetiology of CH with a variable 
penetrance, and rare overall incidence. 
In 2012, we analysed exon3 and exon4 of PAX8 in 300 CH patients, and then 
reported a heterozygous missense mutation (c.G92>A, p.R31H) and a variation 
(c.122G>T, p.G41V) in PAX8, showing that the PAX8 mutation rate (0.67%) is very 
low in CH patients in China [26]. In 2015, we collected 63 TD patients and found a 
heterozygous missense de novo mutation (c.155G>C, p.R52P) in PAX8 by sequencing 
exon3 and exon4; the mutation rate in Chinese TD patients is 1.59% [27]. The mutation 
rate of PAX8 in TD patients is obviously higher in CH patients, illustrating PAX8 
induced CH by influencing thyroid development or migration from a different aspect. 
To further determine the mutational frequencies of PAX8 in Chinese TD patients, we 
expanded the sample size to 289 and analysed all the 12 exons and exon-intro 
boundaries. Ultimately, we discovered three novel variants; the mutation rate was 
1.03%.  
Conclusion 
We conducted the largest worldwide PAX8 mutation screening so far in TD patients, 
and three novel PAX8 nonsense variants were identified in three of 289 TD cases; the 
mutation rate of PAX8 was 1.03%. However, there are still two limitations in this study: 
first, we did not construct the three variants for functional verification; and second, we 
did not make the genetic analysis in familial cases due to lack of samples from their 
parents. Therefore, it is necessary to explore the mechanism for the effects of mutations 
and screen the mutations of PAX8 among large samples in future research. 
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Table 1. The primer sequence for polymerase chain reaction (PCR) of PAX8 
Prime
r 
Sequence 
T
m 
PCR 
product 
Product length 
(bp) 
E1-F 
AGGGCATCCTACAGAG
ACCA 
55 
Exon 1 547 
E1-R 
TCCCGTTTAACTTGGGA
GGG 
56 
E2-F 
TCCTCCTACTCCTGGCA
GAC 
60 
Exon 2 471 
E2-R 
AGAGATCCCCTCACCG
ATCC 
60 
E3-F 
TTGGGAGTGAGAACTG
GGGA 
60 
Exon 3 421 
E3-R 
GGGGAATTCTCTAGCTG
CCC 
60 
E4-F 
GAGGCCTTTAGCAGAG
GGTG 
60 
Exon 4 451 
E4-R 
GACACCAGAGGCTGCT
TTCT 
60 
E5-F 
GGGTGTCAAAAAGGCG
ACTG 
60 
Exon 5 372 
E5-R 
TCAGTGAATCTGCCCTG
GGA 
60 
E6-F 
ACTCTCACTCCCTGACC
CTC 
60 
Exon 6 446 
E6-R 
CACATGCAGAGCCCCT
ACAA 
60 
E7-F 
GCCCTTTTTCTCCCTCC
ACA 
60 
Exon 7 549 
E7-R 
ATCATCAGGTTGTGCTG
CCA 
60 
E8-F 
TGCCGAGTGGAGTTGA
GAAC 
60 
Exon 8 414 
E8-R CTGGGCCCACCTGGC 59 
E9-F 
CTTGGCTTGTGCGTGTT
CC 
60 
Exon 9 401 
E9-R 
CTCCAAAAGTTGCCGG
AGGA 
60 
E10-F 
GTGGGAATGGCATGGA
GGAA 
60 Exon 10 468 
E10-R 
GTCTCAGCCCCTCCCTT
TTC 
60 
E11-F 
CTCCAACTGTCTCCCCA
ACC 
60 
Exon 11 452 
E11-R 
CATGGGCTTGAGAAGC
AGGA 
60 
E12-F-
1 
CAGGGAAGGCTATGGT
GCAA 
60 
Exon 12-1 1508 
E12-
R-1 
GTGAGGTACCCAGCGTT
CAA 
60 
E12-F-
2 
CATCAGAGCTGAGTAG
CCGA 
59 
Exon 12-2 1389 
E12-
R-2 
ACAGTCAACAAACACC
CGCT 
60 
 
 
Table 2. Clinical characteristics of four congenital hypothyroidism (CH) patients 
carrying genetic variants 
Subject Age Sex TSH 
[uIU/mL] 
fT4 
[pmol/L] 
Variant Clinical 
phenotype 
Patient 1 10 Girl 384 4.12 p.Tyr95Ter Hypoplasia 
Patient 2 12 Girl 284 8.71 p.Tyr249T
er 
Hypoplasia 
Patient 3 13 Boy 294 2.8 p.Tyr262T
er 
Athyreosis 
  
  
Figure 1. Sequence maps of PAX8 gene. P1 — sequence of Patient 1 with the PAX8 
variant c.C285G; P2 — sequence of Patient 2 with the PAX8 variant c. T747G; P3 — 
sequence of Patient 3 with the variant c. C786A; C1, C2, and C3 is the corresponding 
sequence in the general population 
 
 
 
 
 
 
 
 Figure 2. Schematic representation of human PAX8 protein domains  
 
 
 
 
 
